Lupus & antiphospholipid syndrome

A retrospective analysis of the safety of tacrolimus use and its optimal cut-off concentration during pregnancy in women with systemic lupus erythematosus: study from two Japanese tertiary referral centers

Arthritis Res TherPublished Retrospective cohort study

Authors' conclusion

Tacrolimus use during pregnancy with SLE and lupus nephritis showed no significant influence on APO, blood pressure, or renal function; therefore tacrolimus may be suitable for controlling lupus activity during pregnancy.

Study context

Population
Pregnant patients with systemic lupus erythematosus (SLE) followed up at two Japanese tertiary referral centres
Participants
124 pregnancies
Exposure
Tacrolimus exposure vs no tacrolimus during pregnancy in SLE
  • Tacrolimusn = 29
Outcome
Adverse pregnancy outcomes (APO): overall, maternal, neonatal and PROMISSE APO
Methodological detailstwo Japanese tertiary referral centres, multivariate logistic regression
  • Two Japanese tertiary referral centres
  • Multivariate logistic regression

Main finding

As reported in the abstract

Adverse pregnancy outcomes (APO), tacrolimus-exposed vs non-exposed pregnancies, multivariate analysis

Overall adverse pregnancy outcome (APO), aOR

0.69; 95% CI, 0.23-2.03

p = 0.50

Maternal APO, aOR

1.17; 95% CI, 0.36-3.83

p = 0.80

Neonatal APO, aOR

1.10; 95% CI, 0.38-3.21

p = 0.86

PROMISSE APO, aOR

0.50; 95% CI, 0.14-1.74

p = 0.27

Observational data: associations, not effects.

Further findings

Blood pressure and estimated glomerular filtration rate (eGFR) during pregnancy and after delivery

Did not differ between the two groups

Tacrolimus concentration > 2.6 ng/ml and reduced preterm birth rate (ROC)

AUC
0.85, 95% CI: 0.61-1.00
Sensitivity
93%
Specificity
75%

APO in LN (subgroup), tacrolimus vs no tacrolimus

Overall APO, OR
1.00; 95% CI, 0.25-4.08; p = 0.98
Maternal APO, OR
1.60, 95% CI, 0.39-6.64; p = 0.51
Neonatal APO, OR
0.71; 95% CI, 0.17-3.03; p = 0.65
PROMISSE APO, OR
0.50; 95% CI, 0.08-3.22; p = 0.47
No increased risk of APO, blood pressure or eGFR during pregnancy and after delivery

Tacrolimus-aspirin combination vs tacrolimus alone

Protective tendency against hypertensive disorders during pregnancy, preeclampsia and low birth weight

Original publication

A retrospective analysis of the safety of tacrolimus use and its optimal cut-off concentration during pregnancy in women with systemic lupus erythematosus: study from two Japanese tertiary referral centers. Arthritis Res Ther. Published 4 January 2024. doi:10.1186/s13075-023-03256-8

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.